A common fallacy of observational medication studies in diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 4, 2015, Pages 317-318

  Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN GLARGINE; METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; CANCER RISK; CARDIOVASCULAR RISK; DIABETES MELLITUS; FATTY LIVER; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; OBESITY; OBSERVATIONAL STUDY; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; FEMALE; MALE; NEOPLASMS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; NEOPLASMS;

EID: 84924560322     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12421     Document Type: Article

References (3)

1. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744.
2. Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus a population-based matched case-control study. JAMA Intern Med 2013; 173: 534-539.
3. Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and incident cancer. Diabetes Obes Metab 2014; 17: 350-362.